Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP36 | Q9P275 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | MMP12 | P39900 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | UQCRB | P14927 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5830664 | 0.91 | USP36 (0.45) | USP36KDM1ASCN9AALDH1A1GAA | |
| SCHEMBL5831705 | 0.89 | MAPT (0.52) | USP36ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL5831173 | 0.85 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL3619659 | 0.83 | ALDH1A1 (0.53) | KDM1AALDH1A1MEN1KMT2AHSD11B1 | |
| SCHEMBL5831555 | 0.82 | ATM (0.49) | ALDH1A1MEN1KMT2AHTTHSD17B10 | |
| SCHEMBL3252292 | 0.81 | HSD11B1 (0.51) | KDM1ASCN9AMEN1KMT2AGAA | |
| SCHEMBL5830800 | 0.80 | HSD11B1 (0.51) | KDM1AALDH1A1KMT2AGAAMAPT | |
| SCHEMBL5830740 | 0.80 | HSD11B1 (0.46) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL5831017 | 0.79 | SMN1; SMN2 (0.48) | ALDH1A1KMT2AGAAMMP1MAPK1 | |
| SCHEMBL5831094 | 0.78 | HSD11B1 (0.56) | SCN9AALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004113310-A1 | USE OF AN INHIBITOR OF 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPOUNDS FOR PROMOTING WOUND HEALING | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | claimed |
| EP-1461327-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2004-09-29 | — | — | EP | claimed |
| US-20030130258-A1 | Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | claimed |
| WO-2003044000-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-05-30 | — | — | WO | claimed |
| US-7074788-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20030130258-A1 | Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130258-A1 | Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics | CPT1A, HSD11B1, CES1 | USP36 3719/4885KDM1A 1842/4885SCN9A 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.